#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics
founderskeepers.substack.com
Convergent Therapeutics is a clinical-stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy that has been licensed to Convergent by Cornell University (USA). If FDA-approved, its flagship therapeutic would be the first antibody approved to direct a radioisotope to prostate cancer.
#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics
#32 Dr Philip Kantoff - Radiopharmaceutical…
#32 Dr Philip Kantoff - Radiopharmaceutical cancer targeting with Convergent Therapeutics
Convergent Therapeutics is a clinical-stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy that has been licensed to Convergent by Cornell University (USA). If FDA-approved, its flagship therapeutic would be the first antibody approved to direct a radioisotope to prostate cancer.